Cancer

Trenbolone Enanthate Market size is set to grow by USD 13.4 million from 2024-2028, Health benefits of using anabolic steroids boost the market, Technavio

NEW YORK, July 15, 2024 /PRNewswire/ -- The global trenbolone enanthate market size is estimated to grow by USD 13.4 million from 2024-2028,…

1 year ago

Active Pharmaceutical Ingredients (API) Market to Surpass USD 351.81 Billion Valuation by 2031, High Demand for Effective Therapeutics and Drugs Driving Market Development | SkyQuest Technology

WESTFORD, Mass., July 15, 2024 /PRNewswire/ -- According to SkyQuest, the global Active Pharmaceutical Ingredients (API) Market size was valued at…

1 year ago

Electrosurgical Devices Market to Reach USD 10.4 Billion by 2034, Fueled by Advanced Technology Ensuring Precision and Safety | Transparency Market Research

The rise in minimally invasive surgeries is a key driver for the global electrosurgical devices market growth, as these procedures require…

1 year ago

3D Cell Culture Market to Transcend USD 11.79 Billion Valuation by 2031, Rising Demand for Regenerative Medicine to Augment Market Development | SkyQuest Technology

WESTFORD, Mass., July 12, 2024 /PRNewswire/ -- According to SkyQuest, the global 3D Cell Culture Market size was valued at USD…

1 year ago

Bedal International raises $11 Million to boost growth of its FlexGRIP® catheter securement devices

DIEPENBEEK, Belgium and ANAHEIM, Calif. , July 12, 2024 /PRNewswire/ -- Bedal International, a Belgian based medical device company delivering next…

1 year ago

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company…

1 year ago

Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)

LOUISVILLE, Ky., July 12, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a…

1 year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST…

1 year ago

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to…

1 year ago